Abstract: The present invention provides a nucleic acid molecule encoding a specific binding molecule capable of binding an h TERT peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 when the peptide is presented by a Class II Major Histocompatibility Complex (MHC), wherein the specific binding molecule comprises a first polypeptide comprising a variable region of an ?-chain and a second polypeptide comprising a variable region of a ?-chain of a T-cell receptor (TCR), and wherein: (a) the variable region of an ?-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the amino acid sequences set forth in SEQ ID NOs: 2, 3 and 4; and (b) the variable region of a ?-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the sequences set forth in SEQ ID NOs: 5, 6 and 7. Recombinant constructs, vectors and host cells comprising such nucleic acid molecules are also provided, as are specific binding molecules encoded by such nucleic acid molecules.

Abstract: The present invention provides a nucleic acid molecule encoding a specific binding molecule capable of binding an h TERT peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 when the peptide is presented by a Class II Major Histocompatibility Complex (MHC), wherein the specific binding molecule comprises a first polypeptide comprising a variable region of an ?-chain and a second polypeptide comprising a variable region of a ?-chain of a T-cell receptor (TCR), and wherein: (a) the variable region of an ?-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the amino acid sequences set forth in SEQ ID NOs: 2, 3 and 4; and (b) the variable region of a ?-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the sequences set forth in SEQ ID NOs: 5, 6 and 7. Recombinant constructs, vectors and host cells comprising such nucleic acid molecules are also provided, as are specific binding molecules encoded by such nucleic acid molecules.

Abstract: The present disclosure relates to compositions comprising compounds or cells able to specifically bind immunoglobulin kappa (IgKappa) and membrane molecule CD 19 under physiological conditions. In particular, the disclosure relates to a combinatorial chimeric antigen receptor (cCAR) with antigen binding domains specific for the antigen CD19 and the immunoglobulin (Ig) Kappa light chain and their expression in immune effector cells to target cells expressing CD19 and IgKappa, and such immune cells for use in treating B-cell cancers.

Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.

Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.

Abstract: Provided herein are compositions and methods for immunotherapy. In particular, provided herein are chimeric antigen receptors, cells expressing chimeric antigen receptors, and use of such cells in immunotherapy (e.g., cancer immunotherapy).

Abstract: The present invention relates to cancer immunotherapy. In particular, provided herein are compositions and methods for improving the efficacy of cell therapies cancer and other diseases.

Abstract: The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated “?1A” frameshift mutation in human TGF?RII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and comprise an ?-chain domain and a ?-chain domain, each chain domain comprising three CDR sequences, wherein a) CDRs 1, 2 and 3 of the ?-chain domain have the sequences of SEQ ID NOs: 2, 3 and 4 respectively; and b) CDRs 1, 2 and 3 of the ?-chain domain have the sequences of SEQ ID NOs: 5, 6 and 7 respectively, and wherein one or more of said CDR sequences may optionally be modified by substitution, addition or deletion of 1 or 2 amino acids. Nucleic acid molecules encoding such TCRs are provided, as are soluble TCR molecules with these CDR sequences.

Abstract: The present invention relates to nucleic acid molecules encoding chimeric antigen receptors (CARs) against the antigen CD37. The CARs disclosed herein have complementarity-determining regions (CDRs) derived from the potent monoclonal anti-CD37 antibody HH1, and may be used in immunotherapy to target cells expressing CD37. Such immunotherapy has a particular use in the treatment of B-cell cancers. The CARs of the present invention are highly functional in the redirection of immune cells to kill CD37+ cells, and include humanised CARs of particular use in medical therapy. The present invention also includes vectors comprising the above-described nucleic acid molecules, immune effector cells expressing the aforementioned CARs and the use of such immune effector cells in therapy, particularly adoptive transfer therapy, for cancer, including B-cell malignancies.

Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.

Abstract: There is disclosed a polypeptide consisting of between 7 and 100 amino acids and comprising: the sequence of the peptide of any one of SEQ. ID NOS: 1 to 145. There is also disclosed a T-cell receptor, or a peptide-binding fragment thereof, wherein the CDR3 region of the beta chain of the T-cell receptor comprises a glycine residue at position 5 from the N-terminus. The T-cell receptor is capable of binding a peptide consisting of the sequence of SEQ. ID NO. 18, when the peptide is presented on an HLA molecule of a first HLA allele.

Abstract: The invention relates to the use of a protein tyrosine phosphatase inhibitor, such as a cross-linker of a protein tyrosine phosphatase (PTP), in particular Sap-1, in the preparation of a medicament for treatment and/or prevention of cancer, and to methods of treating and/or preventing cancer using these inhibitors.

Abstract: The invention relates to phosphopeptides inhibiting protein tyrosine phosphatases, and their uses.